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doi:10.1016/j.ejvs.2010.05.006Abstract Objectives: Several studies have documented a slight but significant deterioration
of renal function after endovascular repair of abdominal aortic aneurysm (AAA) (EVAR). The
aim of this retrospective study was therefore to investigate whether medication with statins
may favourably affect perioperative renal function.
Material and Methods: From January 2000 to January 2008, out of a total cohort of 287 elec-
tive patients receiving endovascular repair of their AAA or aortoiliac aneurysm, 127 patients
were included in the present study, as their medication was reliably retrievable. Patients were
divided according to whether their medication included statins (>3 months). Second, they
were subdivided according to their supra- (SR) or infrarenal (IR) endograft fixation. Serum
creatinine (SCr) and creatinine (CrCl) clearance were determined preoperatively, postopera-
tively, at 6 and 12 months. Patients with known pre-existing renal disease, with incorrect
placement of the stent graft resulting in severe renal artery stenosis, and with occlusion or
renal parenchymal infarction were excluded from the study.
Results: Patients receiving an infrarenal fixation of their graft had no change in the renal func-
tion, regardless whether they were on statins or not. In patients with SR fixation not receiving
statins, a deterioration in renal function was observed in the early postoperative period ((SCr)
preoperative vs. SCr postoperative: 1.02 0.2 vs. 1.11 0.28, p< 0.001 and (Cr.Cl) preopera-
tive vs. Cr.Cl postoperative: 74.1 21.4 vs. 68.0 21.4, p< 0.001), whereas patients on sta-
tins experienced no change in renal function (SCr preoperative vs. SCr postoperative: 0.99
 0.24 vs. 1.02  0.20 n.s. and Cr.Cl preop vs. Cr.Clpostop.: 76.4  19.1 vs. 74.28  20.50,
n.s.). During follow-up, a constant worsening of renal function at 6 and 12 months was
observed, irrespective of the medication with statins.aneurysm; EVAR, Endovascular aortic repair; SR, Suprarenal; IR, Infrarenal; SCr, Serum creatinine;
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Evidence that Statins Protect Renal Function During Endovascular Repair of AAAs 609Conclusions: The present study suggests a slight immediate deterioration of the renal func-
tion using (SR) fixation, and this could be prevented by the use of statins. During follow-up,
statins did not protect from further renal deterioration. Broader studies are needed to
confirm a definitive relation between statin use and renal protection during the endovascu-
lar repair of AAA.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Although endovascular repair of abdominal aortic aneurysms
(AAA) has been proven to reduce systemic ischae-
miaereperfusion injury effects,1 renal impairment occurs in
a subset of patients.2,3 The impairment is multifactorial, and
various mechanisms e such as nephrotoxicity of the admin-
istered contrast medium,4e6 micro- or macroembolisation
into the renal arteries due to aortic manipulation of endo-
vascular materials,6,7 and an induced inflammatory response
e are potentially harmful. The role of suprarenal (SR) stent
fixation, as an additional factor of renal function worsening,
remains unclear and debatable.8e10
There is accumulating evidence that statins have bene-
ficial effects on the vascular tree, independent of their
classical actions on lipoproteins. They induce an improve-
ment of endothelial dysfunction, and an increase in nitric
oxide bioavailability and antioxidant effect. Furthermore,
the anti-thrombotic effect, its anti-inflammatory properties
and the stabilisation of atherosclerotic plaques contribute to
fewer vascular ‘accidents’.11,12 In addition, a putative
immunosuppressive activity and an indirect effect, through
a combination of modulating mechanisms in renal function,
may play a role in patients undergoing AAA repair.11,12
Based on these beneficial effects of statins, we investi-
gated the effect of statin medication on renal function of
patients undergoing endovascular aortic aneurysm repair
(EVAR).
Patients and Methods
Study design and population study
A retrospective, single-centre, non-randomised study was
conducted to evaluate an eventual protective role of sta-
tins in renal response after EVAR in infrarenal (IR) aortic
aneurysms. From January 2000 to January 2008, 287 elec-
tive patients were treated with endovascular procedures
for pathology of the aorta, in our tertiary care university
hospital, out of which 127 patients could be included in the
study. The indication was an aneurysm larger than 5 cm,
and the type of stent-graft device was selected according
to the anatomic appearance of the aneurysm and in
accordance with published guidelines.13
The database for the 127 patients was prospectively
recorded, whereas the statin use was retrospectively ana-
lysed. Risk factors and clinical data were classified according
to the Society for Vascular Surgery/International Society for
Cardiovascular Surgery reporting standards14 (Table 1).
End points of study
The primary end point was to investigate the hypothesis
that medication with statins for more than 3 monthspreoperatively may positively affect postoperative renal
function, compared with cases in which this medication was
not taken. The secondary goal was to examine whether the
type of fixation would have a negative influence on renal
function and the role of statins in such a case.Patient selection, grouping and inclusion and
exclusion criteria
Of the 287 patients, there were not sufficient and available
computerised data for 101 patients during the period
2000e03, for the medication, the biochemical markers and
the follow-up. These 101 patients were excluded from the
study. The rest of the patients were grouped into two main
groups: patients receiving chronic (>3 months) medication
with statins, and patients not receiving statins. Patients in
these two groups were then subgrouped according to the
endograft fixation type (SR or infrarenal (IR)). Patients with
pre-existing vasculitis taking cortisone and patients with
a history of a known preoperative renal disease or a serum
creatinine (SCr) concentration >1.5 mg dle1 or >132 mmol
were eliminated from the study. Patients with thoraco-
abdominal, juxtarenal aortic aneurysms, dissecting aneu-
rysms, aortic para-anastomotic pseudo-aneurysms and
ruptured aneurysms were also excluded from this study.
Finally, patients in whom an incorrect placement of the stent
graft was documented, resulting in severe renal artery
stenosis, occlusion and renal parenchymal infarction, were
alsoeliminated from the study. Exclusion criteria andnumbers
of patients excluded are analytically described in Table 2.
Endovascular technique and contrast infused
A team of vascular surgeons performed all EVARs in an oper-
ating room equipped with a portable C-arm (Philips BV 300),
with angiographic and road-mapping capabilities. During the
past 2 years, the procedures were performed in an Angio-
Suite operating theatrewith a ceilingmountedC-Arm (Philips,
Allura Xper FD20). A variety of endovascular type stent grafts
were used (Table 3). Contrast medium was infused for the
angiogram just before the deployment of the stent graft main
body, then before deployment of the contralateral and ipsi-
lateral iliac leg extension, to visualise the hypogastric artery,
and finally, at the end of the procedure (completion angiog-
raphy). The protocol of contrast medium infusion during EVAR
was identical for all patients.
Renal function assessment and follow-up
The renal function was assessed by SCr concentration and
its clearance preoperatively, on day 3 postoperatively at 6
Table 1 Patient demographics and preoperative risk factors. Values are expressed as mean  S.D. and percentages. n.s.: Not
significant, ASA: American Society of Anesthesiologists, BMI: Body mass index. Values in bold are statistically significant.
Statin users
(nZ 58)
Statin no users
(nZ 69)
p Value
Male Gender 51/58 (88%) 58/69 (88.5%) >.05
Age (Years) 70.6 8.8 72.3 7 >.05
BMI 27.9 3.2 26.4 4.4 .03
AAA Diameter 5.74 1.1 5.9 1.2 >.05
ASA Classification 2.85 0.6 2.91 0.4 >.05
Type I and II 25% 34%
Type III 62% 62%
Type IV 11% 4%
Type V 2% e
Active smokers 62% 59% >.05
Hyperlipidemia 38% 12% <.001
Diabetes Mellitus 18.5% 11 % >.05
Pulmonary Disease 29% 33% >.05
Cardiac status
Asymptomatic 34% 40% >.05
Hypertension 48% 56% >.05
Coronary Disease 55% 53% >.05
Arrhythmic Disorders 5% 9% >.05
Valve Insufficiency 10% 6% >.05
Cerebrovascular disease 21% 19.5% >.05
Type of statin
Atorvastatin (-40 mg) 10/58 (17.2%) e
Fluvastatin (40 mg) 1/58 (1.7%) e
Lovastatin (40 mg) 2/58 (3.4%) e
Pravastatin (-40 mg) 6/58 (10.3%) e
Simvastatin (-40 mg) 39/58 (67.2%) e
Medications
Antiplatelet Drugs (Asp Clop) 78% 77% >.05
Calcium Antagonists 16% 13% >.05
ACE Inhibitors 35% 32% >.05
b-Blockers 42% 32% >.05
Nitrates 12% 10% >.05
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(CT) control. Creatinine clearance (CrCl) was then calcu-
lated according to the CockcrofteGault formula.15
Helical CT scans were performed on each patient
postoperatively before admission, at 6 and 12 months,
and then annually thereafter. CT at shorter intervals or
angiography was performed when indicated. The follow-
up CT angiograms were used not only to identify the
presence of endoleaks or stent migration and to confirmTable 2 Exclusion criteria. In parenthesis the number of patien
Patients with known preexisting renal disease, SCr > 1.5 mg/dL o
Patients with preexisted vasculitis affecting the kidneys, and pat
History of nephrectomy, or cancer of the urologic system (3)
Thoracoabdominal, dissecting, juxtarenal aortic and para-anasto
Symptomatic and ruptured aneurysms (5)
Procedures complicated by peripheral thromboembolism, limb is
Patients with inappropriate endostent placement, and patients w
Patients in which medication with or without statins could not bthe patency of the stent graft and renal arteries, but also
to detect the presence of any renal parenchymal perfu-
sion defects.
Drug medication
All prescriptions and medications were noted by confirmed
intake of the patient and the referral letter from the
general practitioner. Drugs listed were as follows: statins,ts excluded.
r >132 micromol (21)
ients receiving cortisone (2)
motic aortic aneurysms (23)
chemia and myoglobinuria (2)
ith covered polar (accessory) artery (3)
e determined (101)
Table 3 Operation characteristics and endostent type. n.d.: not determined.
Statin users
(nZ 58)
Statin not users
(nZ 69)
p Value
Suprarenal fixation 31/58 (53%) 42/69 (61%) >.05
Endostent type n.d.
Anaconda 7 (12%) 8(11.6%)
AneuRX e 1(1.45%)
Endofit 1(1.75%) e
Endologix 1(1.75%) 1(1.45%)
Endurant 2 (3.5%) e
Excluder 18 (31%) 15(21.7%)
Fortron e 2(2.9%)
Lifepath e 2(2.9%)
Talent 3(5%) 3(4.3%)
Zenith 26(45%) 37(53.6%)
Operative Time (min) 136 33 (63e189) 144 42 (85e320) >.05
Blood loss (ml) 447 362 (100e2400) 385 242 (0e1000) >.05
Postoperative Discharge 6.7 2.4(4e15) 7.7 3.6 (3e21) >.05
30-d Mortality 0% 0% e
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inhibitors, calcium channel blockers, nitrates and digoxin.
The medication was not discontinued before or after the
operation. Patients unable to take medications orally per-
ioperatively were switched to intravenous formulas, or the
oral medications were restarted as soon as possible after
surgery e normally, the following day.
Statistical analysis
Descriptive statistics were completed with a mean S.D. The
comparison of continuous variables was made by using the
ManneWhitney test for independent variables and the Wil-
coxon signed-rank test for dependent variables. Categorical
variables were compared with the Fisher’s exact test. Differ-
enceswere considered significant if the p valuewas<0.05. All
evaluationswere performedusing the statistical package SPSS
for MS-Windows, release 17.0 (SPSS, Chicago, IL, USA).
Results
All 127 patients underwent successful placements of a stent
graft. Patients’ characteristics and risk factors are analyt-
ically described in Table 1, while operation characteristics
and stent-graft type-related data are included in Table 3.
Fifty-eight (46%) of the 127 patients received a chronic
medication with statins. Seventy-three patients (57%) had
a SR attachment of the graft.
No episodes of acute renal failure requiring haemodial-
ysis occurred during the perioperative period. An increase
in SCr> 30% was observed in 7% (9/127) of patients, while
a rise in SCr< 30% was found in 55% (70/127) of all patients.
When considering the entire group of EVAR patients,
a statistically significant increase of SCr (1.04 0.22 vs.
1.07 0.26; pZ 0.04) and a decrease of CrCl (74.7 20.7
vs. 64.16 19.1, pZ 0.019) were observed between the
preoperative and postoperative periods. During follow-up,
further deterioration of the renal function after 6 months
and 12 months was also observed (Table 6 available online).Statins vs. no statins
Both groups showed similarities, especially in their demo-
graphics, and also revealed certain differences, particu-
larly in terms of their risk profiles (Table 1). Baseline
preoperative SCr and glomerular filtration rate (GFR) were
similar between the two groups (Table 4). In patients
receiving statins, SCr remained unchanged (SCrpreop vs.
SCrpostop.: 1.03 0.23 vs. 1.02 0.21, p> 0.05), as did
CrCl (CrClpreoperative vs. CrClpostoperative :75.9 20.2
vs. 76.79 20.8, p> 0.05), in contrast to non-statin users
(SCrpreop vs. SCrpostop.: 1.02 0.2 vs. 1.11 0.28,
p< 0.001 and CrClpreop vs. CrClpostop.: 74.1 21.4 vs.
68.0 21.4, p< .001). An increase in SCr> 30% was
observed in 5.1% of patients receiving statins, and in 8.7% of
patients who were not under statin prescriptions (p< 0.05).
A less than 30% rise in SCr, associated with a decrease in
CrCl, was found in 43.1% of statin users and in 65.3% of no
users (p< 0.05). A stable creatinine value was documented
in 51.8% of statin users and in 26% of non-statin users
(p< 0.05) (Table 5).
During follow-up, a statistically significant rise in renal
function markers was observed at 6 and 12 months in both
groups.
IR vs. SR fixation
There was no difference in procedure time, estimated
blood loss or contrast volume between the IR and SR
fixation groups. Baseline preoperative levels of SCr were
also similar between the two groups. Although the
preoperative median CrCl value was numerically slightly
higher in the SR fixation group, this was not statistically
different to the value in the IR fixation group (Table 7
available online).
There were no relevant changes in the SCr and the CrCl
in the IR fixation group after EVAR. On the contrary, the
postoperative SCr value, as well as the CrCl, differed
significantly from the preoperative values in patients with
Table 4 Subgroup analysis between statin users and non-statin users. Mean SCr, CrCl in statin users and no users. p value1
preop. compared with postop, p value2 preop. compared with 6 months, p value3 preop. compared with 12 months. Postop. (3):
Postoperatively on day 3. Values in bold are statistically significant.
Statin users
(nZ 58)
Statin no users
(nZ 69)
p Value
Preoperative baseline values
SCr 1.03 0.23 1.04 0.2 >.05
CrCl 75.9 20.2 73.7 21.2 >.05
Postoperatively on day 3
>30 % [SCr 5.1% (3/58) 8.7% (6/69) <.05
<30 % [SCr 43.1% (25/58) 65.3% (45/69) <.05
Unchanged SCr 51.8% (30/58) 26% (18/69) <.05
SCr 1.02 0.21 1.11 0.28 <.05
CrCl 76.79 20.8 68.0 21.4 .023
At 6 months
SCr 1.10 0.13 1.15 0.24 >.05
CrCl 68.0 14.0 61.3 21.3 >.05
At 12 months
(SCr) 1.12 0.16 1.21 0.23 >.05
CrCl 66.06 16.0 56.8 19.0 >.05
Patients receiving statins (nZ 58)
Preop Postop 6 months 12 months p Value1 p Value2 p Value3
SCr 1.03 0.23 1.02 0.21 1.10 0.13 1.12 0.16 >.05 .017 <.001
CrCl 75.9 20.2 76.79 20.8 68.0 14.0 66.06 16.0 >.05 <.001 <.001
Patients not receiving statins (nZ 69)
Preop Postop (3) 6 months 12 months p Value1 p Value2 p Value3
SCr 1.02 0.2 1.11 0.28 1.15 0.24 1.21 0.23 <.001 <.001 <.001
CrCl 74.1 21.4 68.0 21.4 61.3 21.3 56.8 19.0 <.001 <.001 <.001
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in renal function.
During follow-up, both types of patients experienced
steady worsening of renal function groups at 6 and 12
months.
Statin and SR fixation
A relatively low number of patients were included in the
subgroup analysis correlating medication with or without
statins, in patients with SR fixation. Patients taking sta-
tins had no deterioration of renal function during the
immediate postoperative period (SCrpreop vs. SCrpostop.:
0.99 0.24 vs. 1.02 0.20 p > .05 and CrClpreop vs.
CrClpostop.: 76.4 19.1 vs. 74.28 20.50, p> .05),
whereas there was a steady decline in renal function
during follow-up, even among patients taking statins
(Table 5).
Discussion
The present study confirms previous reported studies,
emphasising a slight but significant postoperative deterio-
ration of renal function after endovascular reconstruction
in AAA patients ranging from 3% to 7%.16,17 In this study,
a 3% change was observed in SCr, and a 12% change in CrCl.The subgroup analysis of the study revealed that this
deterioration was observed in patients experiencing
suprarenal fixation. Patients receiving statins did not suffer
from a decrease in renal function in the postoperative
period, as opposed to non-statin users. The subgroup of
individuals with SR fixation prescribed to statins preopera-
tively did not experience any worsening in renal function.
Deterioration of renal function during the 12 months of
follow-up was observed independently of the medication
with statins.
Today, for the treatment of vascular patients, the use of
statins is widely applied in clinical practice. As 3-hydroxy 3-
methylglutaryl (HMG)-CoA reductase inhibitors became
more widely used, their effects beyond lipid lowering
began to emerge. Several trials have documented that
among patients undergoing major vascular surgery, statins
exert cardioprotective effects and reduce postoperative
mortality rates.18e20. Only indirect data exist for the role
of statins in protecting renal function in patients under-
going EVAR. Several studies indicate that statins improve
renal function in the general population of patients with
peripheral artery disease (PAD) and lead to a lower
progression of kidney failure.21,22 Another clinical study
assessing the effects of statins in patients undergoing SR,
aortic cross-clamping for aortic surgery suggested an
association between statins and a preserved renal function,
by reducing reperfusion injury effects.23
Table 5 Subgroup analysis correlating medication with or without statins in patients with suprarenal endostent fixation. Mean
serum creatinine concentration, creatinine clearance and incidence of >30% increase in serum creatinine levels, within
a determined period of time. Postop. (3): Postoperatively on day 3. Values in bold are statistically significant.
Statin users and SR (nZ 31) Statin no users and SR (nZ 42) p Value
Preoperative baseline values
Serum creatinine (SCr) 0.99 0.24 1.03 0.22 >.05
Creatinine clearance 76.4 19.1 78.7 22.3 >.05
Postoperatively on day 3
Serum creatinine 1.02 0.23 1.1 0.28 >.05
Creatinine Clearance 74.47 20.5 71.59 22.2 >.05
At 6 months
Serum creatinine 1.09 0.14 1.15 0.24 >.05
Creatinine Clearance 67.73 17.44 68.68 21.76 >.05
At 12 months
Serum creatinine (SCr) 1.11 0.12 1.23 0.27 >.05
Creatinine Clearance 62.79 18.68 63.41 20.98 >.05
SF and Statin users Group (nZ 31)
Preop Postop 6 months 12 months p value1 p value2 p value3
SCr 0.99 0.24 1.02 0.23 1.09 0.14 1.11 0.12 >.05 >.05 <.001
CrCl 76.4 19.1 74.47 20.5 67.7 17.4 62.79 18.6 >.05 .007 <.001
SF and no Statin users Group (nZ 42)
Preop Postop. (3) 6 months 12 months p value1 p value2 p value3
SCr 1.03 0.22 1.1 0.28 1.15 0.24 1.23 0.27 .003 .002 .003
CrCl 78.7 22.3 71.59 22.2 68.6 21.7 63.41 20.9 .001 .001 .001
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which indicates an early protective role of statins in renal
function after EVAR, emphasis should be given to five
important and relevant pleiotropic effects of statins: (1)
improved endothelial function, (2) modulated inflammatory
response, (3) decreased oxidative stress, (4) maintained
plaque stability24,25 and (5) prevention of thrombus
formation.26,27 These effects could positively interfere with
various mechanisms involved in renal dysfunction after
EVAR. The renal dysfunction after EVAR seems to be
a multifactorial process. Intra-aortic manipulation with
guide wires, catheters and introducer sheaths may lead to
the disruption of arterial plaques and subsequent emboli-
sation into the renal arteries.7,8 There is evidence that
microembolisation is more common in patients undergoing
EVAR, compared with conventional open surgery.28 Statins
may induce plaque stability24,25 and potentially prevent
thrombus26,27 and microemboli, leading to a preservation of
kidney parenchyma integrity.
Renal dysfunction may also be induced by the potential
nephrotoxicity of the relatively high dose of administered
contrast medium during endovascular procedures.4e6
Patients during endovascular reconstruction may poten-
tially receive a large amount of contrast medium. The
pathways for contrast medium-induced nephrotoxicity
include haemodynamic effects, molecule toxicity and
endogenous biochemical disturbances, resulting in tubular
cell injury.29 An increase in oxygen-free radicals and
a decrease in antioxidant enzyme activity, triggered by
contrast medium administration, have been documented as
cellular mechanisms of damage.30,31 The levels of advancedinflammatory response end products appear to increase as
GFR decreases. Furthermore, on the basis that the reactive
oxygen species could be involved in the pathophysiology of
contrast-induced renal dysfunction, a potential prophy-
lactic effect of preoperative N-acetylcysteine administra-
tion has been suggested.32 Attenuation of the inflammatory
response is considered a possible explanation for the
renoprotective actions of statin therapy. Statins may
promote potent systemic antioxidant effects through the
suppression of distinct oxidation and anti-inflammatory
pathways.33,34 In addition, they reduce endothelial
dysfunction, primarily through their ability to enhance
endothelial nitric oxide bioavailability.33,34
The SR fixation is potentially involved in micro-embolic
processes and chronic arterial trauma in renal ostia,
causing an additional aggravation in renal function,28,35
although a recent meta-analysis study concluded that the
role of transrenal fixation in renal function remains unclear
and debatable, due to the absence of convincing data.8 In
the present study, there was a clear impairment of renal
function in patients with SR fixation, who were not statin
users. However, patients with SR fixation and taking statins
did not experience deterioration in renal function. This
indicates the possible role of statins in promoting plaque
stability around renal ostia and preventing micro-embolism
and thrombus formation.24e27
An important finding in our study was continuous renal
deterioration through the 12 months of follow-up, which
was witnessed independently of the use of statins and the
type of fixation. A tendency towards decelerated deterio-
ration at 6 and 12 months of follow-up in patients receiving
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cant. A possible explanation is that statins may play a sta-
bilising role in the postoperative period, during which
complex immune, inflammatory and thrombo-embolic
mechanisms are involved. Whether statins have potential
long-term reno-protective effects is unclear due to rela-
tively controversial data and the heterogeneity of
results.36e38 In addition, risk factors that present in
cardiovascular patients e diabetes mellitus (DM), uncon-
trolled hypertension, progressive atherosclerosis, smoking
and advancing age e can explain further gradual impair-
ment in renal function. There is evidence that statins may
protect kidneys via cholesterol reduction,39 as well as
through their pleiotropic effects upon patients with chronic
kidney disease.40,41 However, it is also believed that statins
may induce proteinuria, impeding albumin uptake by
receptor-mediated endocytosis.42 Although subgroup anal-
yses of major clinical studies and meta-analyses of smaller
trials tend to indicate that statin therapy may stabilise the
GFR, further studies are required to confirm the benefit of
statins in specific populations of patients.36,40,41 The gold
standard for monitoring renal function is the measurement
of GFRs; however, patient compliance for GFR is often
poor. Serum cystatin C, as a more accurate marker of GFR,
is well documented and may be appropriate for further
studies.43
There are limitations to the present study. A direct
effect of contrast media on the kidney and toxic effects on
the tubular cells are involved in the pathophysiology of
contrast medium-induced nephropathy. The amount of
contrast medium administration in each endovascular
procedure was not measured due to absence of available
data. However, as was previously described, an identical
protocol of contrast medium infusion was applied in all
patients (just before the deployment of the stent graft
main body, then before deployment of the contralateral
and ipsilateral iliac leg extension, in order to visualize the
hypogastric artery, and finally, at the end of the procedure)
and the operative time was not different between the two
groups. A second limitation of the study is that the sample
size is relatively small, and larger, perhaps even multi-
centre trials are needed to define the role of statin use for
postoperative renal protection in EVAR. The most important
drawback is the retrospective analysis, but it is question-
able if it would be possible to perform a randomised
controlled study, as most patients with AAA are in need of
statins. The final question is whether all statins are
uniformly effective, or whether type and dosage amount
impact effectiveness.Conclusions
Statins significantly reduce cardiovascular ‘accidents.’ The
present study provides evidence that renal function may be
preserved, due to statins, in patients receiving SR fixation
for AAA during the postoperative period, compared to non-
statin users. Broader studies are needed to definitely
confirm this relation.
This is, to our knowledge, the first report attempting to
investigate the role of statins in renal function protection
after EVAR.Conflict of Interest/Funding
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Supplementary data associated with this article can be
found, in the online version, at doi 10.1016/j.ejvs.2010.
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